Malarone (Proguanil Hydrochloride, Atovaquone)

The combination works by targeting two essential parasite pathways. Atovaquone inhibits the mitochondrial electron transport chain, disrupting energy production, while proguanil is converted to cycloguanil, which blocks the parasite’s dihydrofolate reductase, impairing folate synthesis. Together they provide a synergistic antimalarial effect.

The dose of Malarone is set by the prescribing clinician based on the patient’s age, weight, indication (prevention or treatment), and renal or hepatic function. Dosing recommendations are provided in the product label and should be followed exactly as directed by a healthcare professional.

Malarone is classified as pregnancy category B, indicating that animal studies have not shown risk but there are limited human data. It may be used during pregnancy when the benefit outweighs potential risk. During breastfeeding, the decision should consider the infant’s exposure versus maternal need for malaria protection.

To order Malarone, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials. The sales team then replies with pricing, availability, shipping details and any required import documentation.

Malarone offers a convenient once‑daily tablet regimen and combines two mechanisms of action, which reduces the risk of resistance compared with single‑agent drugs such as chloroquine. It is generally well tolerated but may be more expensive than older agents. Choice of therapy depends on regional resistance patterns, patient tolerance and cost considerations.

Malarone tablets should be stored at ambient temperature, preferably below 25 °C, in their original blister pack to protect from moisture and light. Keep the medication out of reach of children and do not use if the packaging is damaged or the tablets appear discoloured.

Malarone is taken orally with food or a milky drink to improve absorption. For prophylaxis, it is usually started 1–2 days before entering a malaria‑risk area, taken daily throughout the stay, and continued for 7 days after leaving. For treatment, the full prescribed course should be completed even if symptoms improve.

Serious adverse events, although rare, include severe skin reactions such as Stevens‑Johnson syndrome, liver injury manifested by jaundice or elevated enzymes, and hemolytic anemia in patients with glucose‑6‑phosphate dehydrogenase deficiency. Patients should seek immediate medical attention if they develop rash, yellowing of the skin or eyes, or dark urine.

Malarone is contraindicated in individuals with known hypersensitivity to either component, in patients with severe renal impairment (creatinine clearance <30 mL/min) without dose adjustment, and in those with G6PD deficiency who have experienced hemolysis with related drugs. Clinicians should also exercise caution in patients with significant liver disease.